PMID- 20868717 OWN - NLM STAT- MEDLINE DCOM- 20110316 LR - 20211020 IS - 1879-1166 (Electronic) IS - 0198-8859 (Print) IS - 0198-8859 (Linking) VI - 71 IP - 12 DP - 2010 Dec TI - Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. PG - 1191-6 LID - 10.1016/j.humimm.2010.09.012 [doi] AB - Humoral immune responses to mismatched donor human leukocyte antigen (HLA) and major histocompatibility complex (MHC) class I-related chain A (MICA) have been reported to contribute to immunopathogenesis of antibody-mediated rejection (AMR) in the early period and cardiac allograft vasculopathy (CAV) in the late period after cardiac transplantation (HTx). The goal of this study is to define the roles of donor-specific antibodies (DSA) and anti-MICA in AMR and CAV. A total of 95 post-HTx recipients were enrolled; 43 patients in the early period (12 months post-HTx). Development of DSA and anti-MICA were serially monitored using Luminex. Development of DSA (AMR+: n = 6/8.75%, AMR-: n = 4/35.11%, p = 0.009) and anti-MICA (AMR+: n = 5/8.63%, AMR-: n = 4/35.11%, p = 0.002) was significantly associated with AMR. AMR+DSA+ patients demonstrated increased anti-MICA levels compared with AMR+DSA- patients (p=0.01). Serial monitoring revealed DSA (2.7 +/- 1.4 months) preceded development of anti-MICA (6.5 +/- 2.1 months) in recipients diagnosed with AMR at 8.3 +/- 2.5 months post-HTx. Development of DSA (CAV+: n = 8/12.67%, CAV-: n = 5/40.13%, p = 0.004) and anti-MICA (CAV+: n = 9/12.75%, CAV-: n = 5/40.13%, p = 0.001) was significantly associated with CAV. CAV+DSA+ patients demonstrated increased anti-MICA levels compared with CAV+DSA- patients (p = 0.01). Antibodies to HLA are associated with and precede development of anti-MICA in AMR and CAV. Therefore, DSA and anti-MICA can be used as noninvasive markers for monitoring AMR and CAV. CI - Copyright (c) 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. FAU - Nath, Dilip S AU - Nath DS AD - Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Angaswamy, Nataraju AU - Angaswamy N FAU - Basha, Haseeb Ilias AU - Basha HI FAU - Phelan, Donna AU - Phelan D FAU - Moazami, Nader AU - Moazami N FAU - Ewald, Gregory A AU - Ewald GA FAU - Mohanakumar, T AU - Mohanakumar T LA - eng GR - T32 HL007776/HL/NHLBI NIH HHS/United States GR - T32 HL007776-15/HL/NHLBI NIH HHS/United States GR - T32 HL07776/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20100921 PL - United States TA - Hum Immunol JT - Human immunology JID - 8010936 RN - 0 (Antibodies) RN - 0 (HLA Antigens) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (MHC class I-related chain A) SB - IM MH - Adult MH - Aged MH - Antibodies/*immunology MH - Antibody Specificity MH - Coronary Stenosis/diagnosis/*immunology MH - Female MH - Graft Rejection/diagnosis/*immunology MH - HLA Antigens/*immunology MH - Heart Transplantation/*immunology MH - Histocompatibility Antigens Class I/*immunology MH - Humans MH - Male MH - Middle Aged MH - *Tissue Donors MH - Transplantation, Homologous PMC - PMC2995271 MID - NIHMS247554 EDAT- 2010/09/28 06:00 MHDA- 2011/03/17 06:00 PMCR- 2011/12/01 CRDT- 2010/09/28 06:00 PHST- 2010/06/10 00:00 [received] PHST- 2010/08/17 00:00 [revised] PHST- 2010/09/16 00:00 [accepted] PHST- 2010/09/28 06:00 [entrez] PHST- 2010/09/28 06:00 [pubmed] PHST- 2011/03/17 06:00 [medline] PHST- 2011/12/01 00:00 [pmc-release] AID - S0198-8859(10)00505-7 [pii] AID - 10.1016/j.humimm.2010.09.012 [doi] PST - ppublish SO - Hum Immunol. 2010 Dec;71(12):1191-6. doi: 10.1016/j.humimm.2010.09.012. Epub 2010 Sep 21.